Liver failure
Conditions
Interventions
Standard Treatment Group:Li's artificial liver support combined with N-acetylcysteine (NAC) standard dosing regimen (loading dose: D1 8g infused over 1h
2g infused over 4h
6g infused over 16h
D2 4g q12h
D3 4g q12h)
Simplified Regimen Group:Li's artificial liver support combined with N-acetylcysteine (NAC) simplified dosing regimen (D1 4g q6h (>2h)
D2 4g q12h (>2h)
Sponsors
Shulan (Hangzhou) hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age greater than or equal to 18 years old and less than 70 years old 2. INR>1.5 3. TB>10 times ULN 4. Hepatitis B surface antigen or hepatitis B DNA positive 5. The subject (or guardian) has signed the informed consent form
Exclusion criteria
Exclusion criteria: 1. Liver failure caused by non hepatitis B virus 2. Pregnant women or women planning to conceive 3. Post transplant patients 4. Merge tumor patients 5. Combining patients with immune disorders and long-term use of immunosuppressants and/or glucocorticoids 6. Patients with significant impact on prognosis due to the combination of other serious chronic diseases 7. Merge patients with other chronic organ dysfunction disorders 8. Merge active bleeding patients 9. Acetylcysteine allergy or intolerance 10. Other researchers believe that those who cannot complete clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival rate (4 and 12 weeks); | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reactions related to acetylcysteine;The changes in MELD score and COSSH score;Laboratory indicators: Blood biochemical tests show changes in TBil, PTA (INR), etc;Survival rates at 24 and 48 weeks; | — |
Countries
China
Contacts
Public ContactGao Hai
Shulan (Hangzhou) hospital
Outcome results
None listed